Drugs / H-1PV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01301430 | Sep 2011 → May 2015 | glioblastoma | Oryx GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H-1PV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01301430 ↗ |
| Known as | ParvOryx (brand name of H-1PV) | “ParvOryx (brand name of H-1PV)” NCT01301430 ↗ |
| Route | Intravenous | “intratumorally or intravenously” NCT01301430 ↗ |